With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer diagnosis.
The Kompass website serves as a digital hub compiling dozens of kidney cancer support resources in one place. Eisai developed the site in partnership with advocacy organizations KCCure, KidneyCAN, the Kidney Cancer Association and the National Kidney Foundation.
The online compendium currently features around four dozen resources from the five partners, with a smaller, more specific list curated for each visitor based on three questions: whether they’re a patient or caregiver, where they are in the treatment process and what type of support they’re looking for.
Available resources include educational guides and videos walking through topics like medical terminology, treatment options and kidney cancer’s impacts on daily life, as well as access to one-on-one support services like helplines, peer mentoring programs and more.
The Kompass site also highlights several firsthand stories from kidney cancer patients and their loved ones, with links to view their full testimonials on the nonprofit partners’ websites.
The site is aimed at helping people make informed treatment decisions more quickly and confidently amid the often overwhelming influx of information that comes with a cancer diagnosis, according to a Thursday release unveiling Kompass. It was developed based on focus group conversations with patients and caregivers about the types of support that would be most helpful to them.
“There are exceptional resources available for people facing kidney cancer, but we heard from patients and caregivers that they can be difficult to find, especially when navigating a new diagnosis,” Teresa Cronin, VP of corporate communications and patient advocacy at Eisai, said in the release. “We saw an opportunity to address this unique challenge—by connecting the community with trusted information and support—and we’re grateful to have passionate partners eager to collaborate on the creation of Kompass.”
Cronin added, “At Eisai, our human health care mission means bringing tangible resources to the communities we serve beyond the medicines we make, and we’re proud to have put our mission into action with this new initiative.”
The Kompass hub is unbranded, but Eisai sells Lenvima as part of a combination treatment for advanced cases of renal cell carcinoma, the most common type of kidney cancer.